Experimental HCV Drugs
Experimental HCV Drugs
AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 06 November 2013 00:00
- Written by Keith Alcorn
A 2-drug combination of direct-acting antivirals developed by Merck, MK-5172 and MK-8742, with or without ribavirin, achieved very high cure rates in patients with genotype 1 hepatitis C in a small study presented this week at the 64th AASLD Liver Meeting in Washington, DC.
AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 November 2013 00:00
- Written by Keith Alcorn
A combination of 3 direct-acting antivirals developed by Bristol-Myers Squibb --daclatasvir, asunaprevir, and BMS-791325 -- cured chronic hepatitis C virus (HCV) infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson from the University of Colorado reported this week at the 64thAASLD Liver Meeting in Washington, DC. The combination proved equally effective in people with genotype 1a and 1b HCV.
AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 03 November 2013 00:00
- Written by Liz Highleyman
Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced genotype 1 chronic hepatitis C patients with advanced liver fibrosis or cirrhosis, according to the latest findings from the ELECTRON trial presented yesterday at the 64th AASLD Liver Meeting in Washington, DC. A related analysis of previously untreated people without cirrhosis found that reducing treatment duration to 6 weeks led to relapses.
AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 04 November 2013 00:00
- Written by Keith Alcorn
A 2-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virological response (SVR) in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need for pegylated interferon or ribavirin, Eric Lawitz from the Texas Liver Institute reported Sunday at the 64th AASLD Liver Meeting in Washington, DC. In people who had failed to respond to a previous course of pegylated interferon and ribavirin, the same combination achieved SVR in 90%.
AASLD 2013: Simeprevir + Sofosbuvir Produces High Sustained Response Rates for Hard-to-treat Patients
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 03 November 2013 00:00
- Written by Liz Highleyman
A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course of treatment or triple therapy including ribavirin, according to late-breaking findings from the COSMOS trial presented this week at the 64thAASLD Liver Meeting in Washington, DC. The study also showed that 100% of treatment-naive patients and null responders with advanced fibrosis or cirrhosis achieved early sustained response at 4 weeks post-treatment using the same dual regimen.
More Articles...
- FDA Advisory Committee Gives Positive Opinions on HCV Drugs Simeprevir and Sofosbuvir
- EACS 2013: Faldaprevir Demonstrates Good Early Response in Genotype 1 HIV/HCV Coinfection
- Coverage of the 14th European AIDS Conference
- EACS 2013: Simeprevir with Interferon Effective for Genotype 1 HIV/HCV Coinfected People
Web Design and Development by